FR3048884B1 - Composition pour l'administration par voie orale d'au moins un principe actif a un sujet - Google Patents
Composition pour l'administration par voie orale d'au moins un principe actif a un sujet Download PDFInfo
- Publication number
- FR3048884B1 FR3048884B1 FR1652329A FR1652329A FR3048884B1 FR 3048884 B1 FR3048884 B1 FR 3048884B1 FR 1652329 A FR1652329 A FR 1652329A FR 1652329 A FR1652329 A FR 1652329A FR 3048884 B1 FR3048884 B1 FR 3048884B1
- Authority
- FR
- France
- Prior art keywords
- composition
- subject
- oral administration
- active substance
- active principle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000013543 active substance Substances 0.000 title 1
- 239000002245 particle Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000004067 bulking agent Substances 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 239000000017 hydrogel Substances 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 239000003223 protective agent Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229920005989 resin Polymers 0.000 abstract 1
- 239000011347 resin Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne une composition pour l'administration par voie orale d'au moins un principe actif à un sujet. Cette composition comprend des particules d'hydrogel, avantageusement sous forme humide ou sèche, comprenant : - ledit au moins un principe actif, - au moins un polysaccharide gélifiant, - au moins un agent de charge, et - au moins un agent protecteur, choisi parmi les protéines et/ou les résines alimentaires, aptes à conférer une protection dudit au moins un principe actif dans un milieu dont le pH est inférieur à 5,5, lesquelles particules sont aptes à libérer au moins une partie dudit au moins un principe actif dans un milieu dont le pH est supérieur à 5,5.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1652329A FR3048884B1 (fr) | 2016-03-18 | 2016-03-18 | Composition pour l'administration par voie orale d'au moins un principe actif a un sujet |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1652329A FR3048884B1 (fr) | 2016-03-18 | 2016-03-18 | Composition pour l'administration par voie orale d'au moins un principe actif a un sujet |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3048884A1 FR3048884A1 (fr) | 2017-09-22 |
FR3048884B1 true FR3048884B1 (fr) | 2021-07-30 |
Family
ID=56555469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1652329A Active FR3048884B1 (fr) | 2016-03-18 | 2016-03-18 | Composition pour l'administration par voie orale d'au moins un principe actif a un sujet |
Country Status (1)
Country | Link |
---|---|
FR (1) | FR3048884B1 (fr) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050226905A1 (en) * | 2001-05-22 | 2005-10-13 | Tien Canh L | Biocompatible compositions as carriers or excipients for pharmaceutical and nutraceutical formulations and for food protection |
ITMI20031617A1 (it) * | 2003-08-06 | 2005-02-07 | Fond Carlo E Dirce Callerio Onlus | Microcapsule a doppio strato di polisaccaridi utilizzabili |
US9089152B2 (en) * | 2009-04-13 | 2015-07-28 | TEAGASC—Agriculture and Food Development Authority | Method of producing microbeads |
CN101856604A (zh) * | 2010-06-04 | 2010-10-13 | 上海理工大学 | 一种用静电喷雾制备益生菌微胶囊的方法 |
US9788563B2 (en) * | 2011-04-15 | 2017-10-17 | Pepsico, Inc. | Encapsulation system for protection of probiotics during processing |
CN103110153A (zh) * | 2013-02-05 | 2013-05-22 | 浙江大学 | 一种果蔬复合颗粒饮料及其制备方法 |
CN104911171A (zh) * | 2015-05-25 | 2015-09-16 | 淮阴工学院 | 以海藻酸钠、明胶复合凹土制备益生菌微胶囊的方法 |
-
2016
- 2016-03-18 FR FR1652329A patent/FR3048884B1/fr active Active
Also Published As
Publication number | Publication date |
---|---|
FR3048884A1 (fr) | 2017-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4374851A3 (fr) | Composition ophtalmique pour le traitement d'une maladie de l' il sec | |
MD20070267A (en) | Gastroresistant pharmaceutical formulation containing rifaximin | |
EP4292650A3 (fr) | Composés hétérocycliques en tant qu'immunomodulateurs | |
WO2007027941A3 (fr) | Compositions et methode de preparation de medicaments a faible solubilite dans l'eau presentant une stabilite accrue | |
MX2019010598A (es) | Composicion farmaceutica que comprende selexipag. | |
TR200801336T1 (tr) | Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler. | |
WO2007019232A3 (fr) | Formulations d'immunoconjugué | |
BR112012016021A2 (pt) | formulações estáveis para liofilização de partículas terapêuticas | |
WO2016196776A3 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
WO2007053197A3 (fr) | Preparations nanoparticulaires a base d'acetaminophene | |
MA38576B2 (fr) | Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières | |
MA31927B1 (fr) | Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives | |
BR112018074311A2 (pt) | composição líquida, e, uso de composição líquida. | |
AU2019339740A8 (en) | CSF-1R antibody formulation | |
WO2007058862A3 (fr) | Composes d’imidazolidinone utiles en tant qu’inhibiteurs de la beta-secretase lors du traitement de la maladie d’alzheimer | |
FR3056909B1 (fr) | Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree | |
FR3048177B1 (fr) | Composition cosmetique biphase et son utilisation par application topique | |
WO2007075572A3 (fr) | Inhibiteurs a base de purine oralement actifs de la proteine de choc thermique 90 | |
MX2017010666A (es) | Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico. | |
FR3048884B1 (fr) | Composition pour l'administration par voie orale d'au moins un principe actif a un sujet | |
HK1120417A1 (en) | Stable nanoparticle formulations | |
EP4327871A3 (fr) | Compositions pharmaceutiques à libération modifiée d'huperzine et leurs procédés d'utilisation | |
FR3042409B1 (fr) | Emulsion comprenant une charge a effet flouteur et un pigment composite a base d'alumine plaquettaire, d'oxyde metallique et d'un agent de traitement de surface | |
WO2018033941A3 (fr) | Compositions pharmaceutiques à base d'ibrutinib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 2 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20170922 |
|
PLFP | Fee payment |
Year of fee payment: 3 |
|
PLFP | Fee payment |
Year of fee payment: 5 |
|
PLFP | Fee payment |
Year of fee payment: 6 |
|
PLFP | Fee payment |
Year of fee payment: 7 |
|
PLFP | Fee payment |
Year of fee payment: 8 |
|
PLFP | Fee payment |
Year of fee payment: 9 |
|
TP | Transmission of property |
Owner name: CAPSULAE, FR Effective date: 20240311 |